NCT06985576Enrolling by invitation
Long-term Study to Evaluate Safety and Persistence of GF-CART01
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 18 (estimated)
- First submitted
- 15 May 2025
- Start date
- 26 Feb 2026
- Primary completion date
- May 2041
- Lead sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
- NCT number
- NCT06985576
What you commit to
- Study type: Observational
- Planned participants: 18
- From 26 Feb 2026 to the primary completion date, May 2041
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Subjects previously enrolled in the study of GF-CART01 (Protocol No.: GF-01-01) and received GF-CART01 infusion
- Subjects or their legal guardians must volunteer to participate in the study and sign the informed consent
- Willingness and ability to comply with protocol-stated requirements, instructions, and restrictions in the investigator's judgement
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.